Geron (GERN) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for Geron's shares. Their GERN share price forecasts range from $3.00 to $7.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $2.42 at the start of the year. Since then, GERN shares have increased by 52.5% and is now trading at $3.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GERN earnings forecast.

Geron Co. (NASDAQ:GERN) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.14 million. Geron had a negative net margin of 30,349.19% and a negative trailing twelve-month return on equity of 91.38%. During the same period last year, the business posted ($0.09) EPS.

ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Principal Healthcare Innovators ETF (BTEC).

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.19%), State Street Corp (5.02%), Wellington Management Group LLP (2.16%), FMR LLC (1.60%), Geode Capital Management LLC (1.59%) and Fairmount Funds Management LLC (1.40%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GERN stock can currently be purchased for approximately $3.69.

Geron (NASDAQ:GERN) has a market capitalization of $1.88 billion and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-141,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.